The A3 adenosine receptor as multifaceted therapeutic target: Pharmacology, medicinal chemistry, and in silico approaches

Medicinal Research Reviews

Volumn 33, Issue 2, 2013, Pages 235-335

  Cheong, Siew Lee ^a   Federico, Stephanie ^b   Venkatesan, Gopalakrishnan ^a   Mandel, Alexander Laurence ^a   Shao, Yi Ming ^a,c   Moro, Stefano ^d   Spalluto, Giampiero ^b   Pastorin, Giorgia ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF TRIESTE   (Italy)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

Agonist; Allosteric modulator; Antagonist; Human A3 adenosine receptor; Molecular modeling; Pharmacology; Therapeutic potential

Indexed keywords

4 ANILINO 2 CYCLOPENTYLIMIDAZO[4,5 C]QUINOLINE; 4 METHOXY N [7 METHYL 3 (2 PYRIDINYL) 1 ISOQUINOLINYL]BENZAMIDE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; ANTIASTHMATIC AGENT; DIHYDROPYRIDINE DERIVATIVE; DU 124482; FLUOROURACIL; G PROTEIN COUPLED RECEPTOR; ISOQUINOLINE; KF 26777; LUF 6000; LUF 6096; METHOTREXATE; N (2,3 DIPHENYL 1,2,4 THIADIAZOL 5(2H) YLIDENE)METHANAMINE; NUCLEOSIDE ANALOG; OT 7999; PACLITAXEL; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QAF 805; QUINOLONE; RADIOLIGAND; THIAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE DERIVATIVE;

ALLOSTERISM; ARTICLE; ASTHMA; BINDING AFFINITY; BRAIN INJURY; BRAIN ISCHEMIA; BREAST CARCINOMA; CELL GROWTH; CLINICAL TRIAL (TOPIC); COLON CANCER; COMPUTER MODEL; DRUG DESIGN; DRUG HALF LIFE; EPILEPSY; GLAUCOMA; HEART INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INFLAMMATION; KIDNEY FAILURE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PROSTATE CANCER; RHEUMATOID ARTHRITIS; SIMULATION; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; UNSPECIFIED SIDE EFFECT; ANIMAL; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CHEMISTRY; DRUG EFFECT; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; REVIEW; SENSITIVITY AND SPECIFICITY;

ANIMALS; BRAIN DISEASES; CARDIOVASCULAR DISEASES; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; PURINERGIC P1 RECEPTOR AGONISTS; RECEPTOR, ADENOSINE A3; SENSITIVITY AND SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

MLCS; MLOWN;

EID: 84873985958     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20254     Document Type: Article

References (364)

1. Gilman AG. G Proteins: Transducers of receptor-generated signals. Annu Rev Biochem 1987;56:615-649.
2. Costanzi S, Ivanov AA, Tikhonova IG, Jacobson KA. Structure and function of G protein-coupled receptors studied using sequence analysis, molecular modeling, and receptor engineering: adenosine receptors. Front Drug Design Disc 2007;3:63-79.
3. 2A agonist and antagonist. J Med Chem 2003;46:4847-4485.
4. Palmer TM, Stiles GL. Identification of threonine residues controlling the agonist-dependent phosphorylation and desensitization of the rat adenosine receptor. Mol Pharmacol 2000;57:539-545.
5. 3 adenosine receptors in human astrocytoma cells: Agonist-mediated desensitization, internalization, and down-regulation. Mol Pharmacol 2002;62:1373-1384.
6. 3) gene. Neurosci Res 1997;29:73-79.
7. Murrison EM, Goodson SJ, Edbrooke MR, Harris CA. Cloning and characterisation of the human adenosine A3 receptor gene. FEBS Lett 1996;384:243-246.
8. Headrick JP, Peart JN, Reichelt ME, Haseler LJ. Adenosine and its receptors in the heart: Regulation, retaliation and adaptation. Biochim Biophys Acta 2011;1808:1413-1428.
9. Tonazzini I, Trincavelli ML, Storm-Mathisen J, Martini C, Bergersen LH. Co-localization and functional cross-talk between A1 and P2Y1 purine receptors in rat hippocampus. Eur J Neurosci 2007;26:890-902.
10. Ciruela F, Ferré S, Casadó V, Cortés A, Cunha RA, Lluis C, Franco R. Heterodimeric adenosine receptors: A device to regulate neurotransmitter release. Cell Mol Life Sci 2006;63:2427-2431.
11. Meyerhof W, Müller-Brechlin R, Richter D. Molecular cloning of a novel putative G-protein coupled receptor expressed during rat spermiogenesis. FEBS Lett 1991;284:155-160.
12. 3 adenosine receptor. Proc Natl Acad Sci USA 1992;89:7432-7436.
13. 3 receptors: Pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci 1994;15:298-306.
14. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5:247-264.
15. 3 receptor functionality humanized mice for the evaluation of the human antagonists. Biochem Pharmacol 2006;71:294-306.
16. 3 receptors are located in neurons of the rat hippocampus. Neuroreport 2003;14:1645-1648.
17. Peart JN, Headrick JP. Adenosinergic cardioprotection: Multiple receptors, multiple pathways. Pharmacol Ther 2007;114:208-221.
18. 3 pretreatment before cardioplegic arrest attenuates postischemic cardiac dysfunction. Ann Thorac Surg 1999;67:1732-1737.
19. 3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart. Cardiovasc Res 1997;33:410-415.
20. Xu Z, Jang Y, Mueller RA, Norfleet EA. IB-MECA and cardioprotection. Cardiovasc Drug Rev 2006;24:227-238.
21. 3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem 1993;268:16887-16890.
22. Szabo C, Scott GS, Virag L, Egnaczyk G, Salzman AL, Shanley TP, Haskó G. Suppression of macrophage inflammatory protein (MIP)-1a production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 1998;125:379-387.
23. 3 receptors on macrophages inhibits tumor necrosis factor-α. Eur J Pharmacol 1996;310:209-216.
24. Thiele A, Kronstein R, Wetzel A, Gerth A, Nieber K, Hauschildt S. Regulation of adenosine receptor subtypes during cultivation of human monocytes: Role of receptors in preventing lipopolysaccharides-triggered respiratory burst. Infect Immun 2004;72:1349-1357.
25. 3 adenosine receoptor. Thromb Haemost 2002;88:123-130.
26. 3 adenosine receptors on human eosinophils elevates intracellular calcium. Blood 1996;88:3569-3574.
27. 3 adenosine receptor in monocyte-drived dendritic cells and recombinant cells. Mol Pharmacol 2003;63:342-350.
28. Hofer S, Ivarsson L, Stoitzner P, Auffinger M, Rainer C, Romani N, Heufler C. Adenosine slows migration of dendritic cells but does not affect other aspects of dendritic cell maturation. J Invest Dermatol 2003;121:300-307.
29. 3 receptors in the mouse dendritic cell line XS-106. Eur J Pharmacol 2003;474:43-51.
30. Gessi S, Varani K, Merighi S, Cattabriga E, Avitabile A, Gavioli R, Fortini C, Leung E, Mac Lennan S, Borea PA. Expression of A3 adenosine receptors in human lymphocytes: Up-regulation in T cell activation. Mol Pharmacol 2004;65:711-719.
31. Suh BC, Kim TD, Lee JU, Seong JK, Kim KT. Pharmacological characterization of adenosine receptors in PGT-beta mouse pineal gland tumour cells. Br J Pharmacol 2001;134:132-142.
32. Merighi S, Varani K, Gessi S, Cattabriga E, Iannotta V, Ulouglu C, Leung E, Borea PA. Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375. Br J Pharmacol 2001;134:1215-1226.
33. Gessi S, Varani K, Merighi S, Morelli A, Ferrari D, Leung E, Baraldi PG, Spalluto G, Borea PA. Pharmacological and biochemical characterization of A3 Adenosine receptors in Jurkat T cells. Br J Pharmacol 2001;134:116-126.
34. 3 adenosine subtype. J Cell Physiol 2007;211:826-836.
35. 3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level. J Rheumatol 2007;34:20-26.
36. 3 adenosine receptor: An enigmatic player in cell biology. Pharmacol Ther 2008;117:123-140.
37. 3 receptors in rat brain. Mol Pharmacol 1995;48:1038-1045.
38. Mozzicato S, Joshi BV, Jacobson KA, Liang BT. Role of direct RhoA-phospholipase D1 interaction in mediating adenosine-induced protection from cardiac ischemia. FASEB J 2004;18:406-408.
39. 3 receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. Mol Pharmacol 2000;58:477-482.
40. 3 receptor expressed in Chinese hamster ovary cells to the extracellular signal-regulated kinase 1/2. Mol Pharmacol 2002;62:1137-1146.
41. Germack R, Dickenson JM. Adenosine triggers preconditioning through MEK/ERK1/2 signalling pathway during hypoxia/reoxygenation in neonatal rat cardiomyocytes. J Mol Cell Cardiol 2005;39:429-442.
42. 3 adenosine receptors: Design of selective ligands and therapeutic prospets. Drugs Future 1995;20:689-699.
43. Cohen MV, Downey JM. Adenosine: Trigger and mediator of cardioprotection. Basic Res Cardiol 2008;103:203-215.
44. 3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res 1994;28:1057-1061.
45. Chen GJ, Harvey BK, Shen H, Chou J, Victor A, Wang Y. Activation of adenosine receptor reduces ischemic brain injury in rodents. J Neurosci Res 2006;84:1848-1855.
46. 3R as a therapeutic target in experimental colitis: Proof by validated high-density oligonucleotide microarray analysis. Inflamm Bowel Dis 2006;12:766-789.
47. Kolachala VL, Bajaj R, Chalasani M, Sitaraman SV. Purinergic receptors in gastrointestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2008;294:G401-G410.
48. 3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. Curr Eye Res 2005;30:747-754.
49. 3 adenosine receptors lower mouse intraocular pressure and act across species. Exp Eye Res 2010;90:146-154.
50. Brown RA, Spina D, Page CP. Adenosine receptors and asthma. Br J Pharmacol 2008;153:S446-S456.
51. 3Ri3 adenosine receptors in sperm. J Biol Chem 2010;285:33662-33670.
52. Sattin A, Rall TW. The effect of adenosine and adenine nucleotides on the cyclic adenosine 3′, 5′-phosphate content of guinea pig cerebral cortex slices. Mol Pharmacol 1970;6:13-23.
53. Ribeiro JA, Sebastião AM, de Mendonça A. Adenosine receptors in the nervous system: Pathophysiological implications. Prog Neurobiol 2003;68:377-392.
54. 2a receptors in the hippocampus. Brain Res 1994;649:208-216.
55. Von Lubitz DK, Simpson KL, Lin RC. Right thing at a wrong time? Adenosine A3 receptors and cerebroprotection in stroke. Ann N Y Acad Sci 2001;939:85-96.
56. 3 adenosine receptors expressed in the brain? Neuroreport 2000;11:1025-1030.
57. 1 receptor-mediated responses in rat hippocampus. J Neurosci 1997;17:607-614.
58. 3 adenosine receptor agonist 2-Cl-IB-MECA facilitates epileptiform discharges in the CA3 area of immature rat hippocampal slices. Epilepsy Res 2004;59:83-94.
59. Macek TA, Schaffhauser H, Conn PJ. Protein kinase C and A3 adenosine receptor activation inhibit presynaptic metabotropic glutamate receptor (mGluR) function and uncouple mGluRs from GTP-binding proteins. J Neurosci 1998;18:6138-6146.
60. 3 receptors mediate inhibition of synaptic transmission in rat cortical neurons. Neuropharmacology 2001;40:85-95.
61. 1 receptors. Drug Deliv Res 2003;58:428-438.
62. 3 adenosine receptor mediates cell spreading, reorganization of actin cytoskeleton, and distribution of Bcl-XL: Studies in human astroglyoma cells. Biochem Biophys Res Commun 1997;241:297-304.
63. 1 receptor agonist. Eur J Pharmacol 1999;369:313-317.
64. von Lubitz DKJE. Adenosine and cerebral ischemia: Therapeutic future or death of a brave concept? Eur J Pharmacol 1999;371:85-102.
65. 3 receptors and viability of astrocytes. Drug Dev Res 1998;45:379-386.
66. Di Iorio P, Kleywegt S, Ciccarelli R, Traversa U, Andrew CM, Crocker CE, Werstiuk ES, Rathbone MP. Mechanisms of apoptosis induced by purine nucleosides in astrocytes. Glia 2002;38:179-190.
67. 3 receptor-induced apoptosis. J Mol Neurosci 2001;17:285-292.
68. D'Alimonte I, Ballerini P, Nargi E, Buccella S, Giuliani P, Di Iorio P, Caciagli F. Staurosporine-induced apoptosis in astrocytes is prevented by A(1) adenosine receptor activation. Neurosci Lett 2007;418:66-71.
69. 3 receptor agonist and cerebral ischaemia: Neuronal and glia effects. Eur J Pharmacol 1999;367:157-163.
70. Dawson VL, Dawson TM. Neuronal ischaemic preconditioning. Trends Pharmacol Sci 2000;21:423-424.
71. 3 receptors on CA1 hippocampal neurotransmission during oxygen-glucose deprivation episodes of different duration. Biochem Pharmacol 2007;74:768-779.
72. 3 receptor agonist-induced neurotoxicity in rat cerebellar granule neurons. Drug Dev Res 1997;40:267-273.
73. 3 adenosine receptor activation and gene knock-out in ischemic-reperfused mouse heart. Cardiovasc Res 2002;53: 147-155.
74. 3 receptor-induced CCL2 synthesis in cultures mouse astrocytes. Glia 2004;46:410-418.
75. 3 receptor suppresses lipopolysaccharide-induced TNF-α production through inhibition of PI-3-kinase/Akt and NF-kB activation in murine BV2 microglial cells. Neurosci Lett 2006;396:1-6.
76. 3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release. Br J Pharmacol 1999;127:188-194.
77. Hannon JP, Bray-French KM, Philips RM, Fozard JR. Further pharmacological characterization of the adenosine receptor subtype mediating inhibition of oxidative burst in human isolated neutrophils. Drug Dev Res 1998;43:214-224.
78. Maggirwar SB, Dhanraj DN, Somani SM, Ramkumar V. Adenosine acts as an endogenous activator of the cellular antioxidant defence system. Biochem Biophys Res Commun 1994;201:508-515.
79. Sawynok J. Adenosine receptor activation and nociception. Eur J Pharmacol 1998;347:1-11.
80. Barraco RA, Swanson TH, Phillis JW, Berman RF. Anticonvulsant effects of adenosine analogues on amygdaloid-kindled seizures in rats. Neurosci Lett 1984;46:317-322.
81. Dragunow M, Goddard GV, Laverty R. Is adenosine an endogenous anticonvulsant? Epilepsia 1985;26:480-487.
82. A receptors. Proc Natl Acad Sci USA 2008;105:15118-15123.
83. Olanrewaju HA, Qin W, Feoktistov I, Scemama JL, Mustafa SJ. Adenosine A(2A) and A(2B) receptors in cultured human and porcine coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2000;279:H650-H656.
84. 3 receptor involvement. Cardiovasc Res 1994;28:1049-1056.
85. 3 receptors mediates preconditioning of isolated cardiac myocytes. Eur J Pharmacol 1997;320:241-248.
86. ATP channel. J Mol Cell Cardiol 2002;34:263-277.
87. 6-(2, 5-dichlorobenzyl)-3′-aminoadenosine-5′-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel. J Pharmacol Exp Ther 2008;324:234-243.
88. 3 receptor agonists reduce hypoxic injury through the involvement of P38 MAPK. Mol Cell Biochem 2010;345:153-160.
89. 3 adenosine receptors decreases heart rate, preserves energetics, and protects ischemic hearts. Am J Physiol Heart Circ Physiol 2002;283:H1562-H1568.
90. 3 adenosine receptor. Circ Res 2002;91:165-172.
91. 3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart. Cardiovasc Res 1997;33:410-415.
92. 3 adenosine receptor-mediated protection of the ischemic heart. Vasc Pharmacol 2005;42:271-279.
93. Verma S, Fedak PW, Weisel RD, Butany J, Rao V, Maitland A, Li RK, Dhillon B, Yau TM. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation 2002;105:2332-2336.
94. 3 adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells. J Mol Cell Cardiol 2010;49:280-286.
95. Suleiman M-S, Halestrap AP, Griffiths EJ. Mitochondria: A target for myocardial protection. Pharmacol Ther 2001;89:29-46.
96. 3 receptor activation protects the myocardium from reperfusion/reoxygenation injury. Am J Physiol Heart Circ Physiol 2002;283:H1307-H1313.
97. Mahaffey KW, Puma JA, Barbagelata NA, Di Carli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999;34:1711-1720.
98. Kopecky SL, Aviles RJ, Bell MR, Lobl JK, Tipping D, Frommell G, Ramsey K, Holland AE, Midei M, Jain A, Kellett M, Gibbons RJ. AmP579 Delivery for Myocardial Infarction REduction study. A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal corony angioplasty: The ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am Heart J 2003;146:146-152.
99. El-Awady MS, Ansari HR, Fil D, Tilley SL, Mustafa SJ. NADPH oxidase pathway is involved in aortic contraction induced by A3 adenosine receptor in mice. J Pharmacol Exp Ther 2011, published online, DOI:10.1124/jpet.111.18082810.1124/jpet.111.180828.
100. Marquardt DL, Gruber HE, Wasserman SI. Adenosine release from stimulated mast cells. Proc Natl Acad Sci USA 1984;81:6192-6196.
101. Madara JL, Patapoff TW, Gillece-Castro B, Colgan SP, Parkos CA, Delp C, Mrsny RJ. 5′-Adenosine monophosphate is the neutrophil-derived paracrine factor that elicits chloride secretion from T84 intestinal epithelial cell monolayers. J Clin Invest 1993;91:2320-2325.
102. Resnick MB, Colgan SP, Patapoff TW, Msrny RJ, Awtrey CS, Delp-Archer C, Weller PF, Madara JL. Activated eosinophils evoke chloride secretion in model intestinal epithelia primarily via regulated release of 5′-AMP. J Immunol 1993;151:5716-5723.
103. Harada N, Okajima K, Murakami K, Usune S, Sato C, Ohshima K, Katsuragi T. Adenosine and selective A(2A) receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation. J Pharmacol Exp Ther 2000;294:1034-1042.
104. Flamand N, Surrette ME, Picard S, Bourgoin S, Borgeat P. Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Mol Pharmacol 2002;62:250-256.
105. Flamand N, Lefebvre J, Lapointe G, Picard S, Lemieux L, Bourgoin SG, Borgeat P. Inhibition of platelet-activating factor biosynthesis by adenosine and histamine in human neutrophils: Involvement of cPLA2alpha and reversal by lyso-PAF. J Leukoc Biol 2006;79:1043-1051.
106. 2B receptor activation. Shock 2001;15:297-301.
107. Russo C, Arcidiacono G, Polosa R. Adenosine receptors: Promising targets for the development of novel therapeutics and diagnostics for asthma. Fundam Clin Pharmacol 2005;20:9-19.
108. 3 adenosine receptor. J Pharmacol Exp Ther 2006;317:172-180.
109. 3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. J Pharmacol Exp Ther 2006;316:71-78.
110. Forte G, Sorrentino R, Montinaro A, Pinto A, Morello S. Cl-IB-MECA enhances TNF-α release in peritoneal macrophages stimulated with LPS. Cytokine 2011;54:161-166.
111. La Sala A, Gadina M, Kelsall BL. G(i)-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK. J Immunol 2005;175:2994-2999.
112. Takahashi HK, Iwagaki H, Hamano R, Wake H, Kanke T, Liu K, Yoshino T, Tanaka N, Nishibori M. Effects of adenosine on adhesion molecule expression and cytokine production in human PBMC depend on the receptor subtype activated. Br J Pharmacol 2007;150:816-822.
113. Szabo C, Scott GS, Virag L, Egnaczyk G, Salzman AL, Shanley TP, Hasko G. Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 1998;125:379-387.
114. 3 adenosine receptor. Thromb Haemost 2002;88:123-130.
115. 3 receptor. J Immunol 2003;170:338-345.
116. Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, Jacobson MA. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem 2000;275:4429-4434.
117. Ali S, Mustafa SJ, Metzger WJ. Adenosine-induced bronchoconstriction in an allergic rabbit model: Antagonism by theophylline aerosol. Inflamm Res 1992;37:165-167.
118. Fan M, Mustafa SJ. Adenosine-mediated bronchoconstriction and lung inflammation in an allergic mouse model. Pul Pharmacol Ther 2002;15:147-155.
119. 3 receptor- and mast cell-dependent and -independent components of adenosine-mediated airway responsiveness in mice. J Immunol 2003;171:331-337.
120. Fan M, Mustafa SJ. Role of adenosine in airway inflammation in an allergic mouse model of asthma. Int Immunopharmacol 2006;6:36-45.
121. Oldenburg PJ, Mustafa SJ. Involvement of mast cells in adenosine-mediated bronchoconstriction and inflammation in an allergic mouse model. J Pharmacol Exp Ther 2005;313:319-324.
122. Van Schoor J, Joos GF, Pauwels RA. Indirect bronchial hyperresponsiveness in asthma: Mechanisms, pharmacology and implications for clinical research. Eur Resp J 2000;16:514-533.
123. Fan M, Qin W, Mustafa SJ. Characterization of adenosine receptor(s) involved in adenosine-induced bronchoconstriction in an allergic mouse model. Am J Physiol Lung Cell Mol Physiol 2003;284:L1012-L1019.
124. 3 receptor. J Immunol 2003;171:338-345.
125. 3 receptor expression and function in eosinophils. Am J Respir Cell Mol Biol 1997;16:531-537.
126. 3 adenosine receptor signaling contributes to airway inflammation and mucus production in adenosine deaminase-deficient mice. J Immunol 2004;173:1380-1389.
127. 3 receptor stimulation inhibits migration of human eosinophils. J Leukoc Biol 1997;62:465-468.
128. 3 receptor antagonist with therapeutic potential. Bioorg Med Chem Lett 2005;15:3081-3085.
129. 3 adenosine receptor antagonist does not attenuate AMP challenge in subjects with asthma. Am J Resp Crit Care Med 2007;175:A682.
130. Bevan N, Butchers PR, Cousins R, Coates J, Edgar EV, Morrison V, Sheehan MJ, Reeves J, Wilson DJ. Pharmacological characterization and inhibitory effects of (2R, 3R, 4S, 5R)-2-(6-amino-2-{[(1S)-2-hydroxy-1-(phenylmethyl)ethyl]amino} -9H-purin-9-yl)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3, 4-furandiol, a novel ligand that demonstrates both adenosine A(2A) receptor agonist and adenosine A(3) receptor antagonist activity. Eur J Pharmacol 2007;564:219-225.
131. Rimmer J, Peake HL, Santos CM, Lean M, Bardin P, Robson R, Haumann B, Loehrer F, Handel ML. Targeting adenosine receptors in the treatment of allergic rhinitis: A randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2007;37:8-14.
132. 3 receptor suppresses lipopolysaccharide-induced TNF-á production through inhibition of PI-3-kinase/Akt and NF-kB activation in murine BV2 microglial cells. Neurosci Lett 2006;396:1-6.
133. Levy O, Coughlin M, Cronstein BN, Roy RM, Desai A, Wessels MR. The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn. J Immunol 2006;177:1956-1966.
134. 3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol 2005;32:469-476.
135. 3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: Involvement of nuclear factor-kappaB in mediating receptor level. J Rheumatol 2007;34:20-26.
136. 3 adenosine receptor expression. Arthritis Res Ther 2006;8:R169.
137. Baggott JE, Morgan SL, Sams WM, Linden J. Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis. Arch Dermatol 1999;135:813-817.
138. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266-273.
139. Laghi Pasini F, Capechhi PL, Di Perri T. Adenosine plasma levels after low dose methotrexate administration. J Rheumatol 1997;24:2492-2493.
140. 3 adenosine receptor as target to treat rheumatoid arthritis: Data from a phase II clinical trial. J Rheumatol 2008;35:41-48.
141. van Troostenburg AR, Clark EV, Carey WD, Warrington SJ, Kerns WD, Cohn I, Silverman MH, Bar-Yehuda S, Fong KL, Fishman P. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. Int J Clin Pharmacol Ther 2004;42:534-542.
142. 3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. Crit Care 2006;10:R65.
143. 3 adenosine receptor provides lung protection against ischemia-reperfusion injury associated with reduction in apoptosis. Am J Transplant 2004;4:1941-1948.
144. 3 adenosine receptor attenuates lung injury after in vivo reperfusion. Anesthesiology 2004;101:1153-1159.
145. 3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. Am J Physiol Regul Integr Comp Physiol 2006;291:R959-R969.
146. 6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis. Eur J Pharmacol 2003;466:323-329.
147. Guzman J, Yu JG, Suntres Z, Bozarov A, Cooke H, Javed N, Auer H, Palatini J, Hassanain HH, Cardounel AJ, Javed A, Grants I, Wunderlich JE, Christofi FL. ADOA3R as a therapeutic target in experimental colitis: Proof by validated high-density oligonucleotide microarray analysis. Inflamm Bowel Dis 2006;12:766-789.
148. Antonioli L, Fornai M, Colucci R, Awwad O, Ghisu N, Tuccori M, Da Settimo F, La Motta C, Natale G, Duranti E, Virdis A, Blandizzi C. The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors. J Pharmacol Exp Ther 2010;335:434-442.
149. 3 receptors in skeletal muscle ischemia and reperfusion injury. Am J Physiol Heart Circ Physiol 2007;293:H3685-H3691.
150. Avni I, Garzozi HJ, Barequet IS, Segev F, Varssano D, Sartani G, Chetrit N, Bakshi E, Zadok D, Tomkins O, Litvin G, Jacobson KA, Fishman S, Harpaz Z, Farbstein M, Yehuda SB, Silverman MH, Kerns WD, Bristol DR, Cohn I, Fishman P. Treatment of dry eye syndrome with orally administered CF101. Ophtalmology 2010;117:1287-1293.
151. Fishman P, Bar-Yehuda S, Madi L, Rath-Wolfson L, Ochaion A, Cohen S, Baharav E. The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther 2006;8:R33.
152. 3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. Biochem Pharmacol 2008;76:482-494.
153. 1 adenosine receptor activation inhibits inflammation, necrosis, and apoptosis after renal ischemia-reperfusion injury in mice. J Am Soc Nephrol 2004;15:102-111.
154. 3 adenosine receptor knockout mice are protected against ischemia- and myoglobinuria-induced renal failure. Am J Physiol Renal Physiol 2003;284:F267-F273.
155. Kim SH, Nam EJ, Kim YK, Ye YM, Park HS. Functional variability of the adenosine A3 receptor (ADORA3) gene polymorphism in aspirin-induced urticarial. Br J Dermatol 2010;163:977-985.
156. Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells. Int J Oncol 2008;32:527-535.
157. Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis: A look outside the nucleus. Science 2000;287:1606-1609.
158. 3 adenosine receptor is highly expressed in tumor versus normal cells: Potential target for tumor growth inhibition. Clin Cancer Res 2004;10:4472-4479.
159. 3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin Cancer Res 2004;10:5895-5901.
160. 3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kB signal transduction pathway. Int J Oncol 2008;33:287-295.
161. Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, Johnson R, Karin M. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 1999;189:1839-1845.
162. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-kB activity. Annu Rev Immunol 2000;18:621-663.
163. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, MacLennan S, Borea PA. Adenosine modulates vascular endothelial growth factor-1 in human glioblastoma cells. Biochem Pharmacol 2006;72:19-31.
164. Morrone FB, Jacques-Silva MC, Horn AP, Bernardi F, Schwartsmann G, Rodnight R, Lenz G. Extracellular nucleotides and nucleosides induce proliferation and increase nucleoside transport in human glioma cell lines. J Neuro-Oncol 2003;64:211-218.
165. Ferkey DM, Kimelman D. GSK-3: New thoughts on an old enzyme. Dev Biol 2000;225:471-479.
166. Cross DA, Alessi DR, Cohen P, Adjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785-789.
167. Fang X, Yu SX, Lu Y, Bast Jr RC, Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc natl Acad Sci USA 2000;24:11960-11965.
168. Novak A, Dedhar S. Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci 1999;56:523-537.
169. Morin PJ. Beta-catenin signaling and cancer. Bioessays 1999;21:1021-1030.
170. 1 cell cycle arrest and apoptosis in human promyelocytic leukemia HL-60 cells. Biochem Pharmacol 2005;70:918-924.
171. Kim SJ, Min HY, Chung HJ, Park EJ, Hong JY, Kang YJ, Shin DH, Jeong LS, Lee SK. Inhibition of cell proliferation through cell cycle arrest and apoptosis by thio-Cl-IB-MECA, a novel A(3) adenosine receptor agonist, in human lung cancer cells. Cancer Lett 2008;264:309-315.
172. 3 adenosine receptor enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model. Neoplasia 2005;7:85-90.
173. 3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res 2001;269:230-236.
174. 3 adenosine receptor as a target for cancer therapy. Anticancer Drugs 2002;13:1-8.
175. Ohana G, Bar-Yehuda S, Arich A, Madi L, Dreznick Z, Silberman D, Slosman G, Volfsson-Rath L, Fishman P. Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101. Br J Cancer 2003;89:1552-1558.
176. 3 adenosine receptor by low agonist concentration induced anti-tumor and myelostimulation effects. Drug Dev Res 2003;58:386-389.
177. 3AR agonist. Anticancer Res 2003;23:2077-2083.
178. 3 adenosine receptor activation in melanoma cells: Association between receptor fate and tumor growth inhibition. J Biol Chem 2003;278:42121-42130.
179. Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, Shpall EJ, Bast Jr RC, Gilbert CJ, Oette DH. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988;318:869-876.
180. 3 adenosine receptor agonist potentiates natural killer cell activity. Int J Oncol 2003;23:1245-1249.
181. 6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide in human leukemia cells. J Cell Physiol 2011, doi: 10.1002/jcp.2277510.1002/jcp.22775.
182. 3 adenosine receptor induces cytoskeleton rearrangement in human astrocytoma cells via specific action on Rho proteins. Ann N Y Acad Sci 2001;939:63-73.
183. 3 adenosine receptor mediates cell spreading reorganization of actin cytoskeleton, and distribution of Bcl-XL: Studies in human astroglioma cells. Biochem Biophys Res Commun 1997;241:297-304.
184. 3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3 kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J Biol Chem 2005;280:19516-19526.
185. 3 receptor stimulation. Anticancer Res 2006;26:43-47.
186. Panjehpour M, Karami-Tehrani F. Adenosine modulates cell growth in the human breast cancer cells via adenosine receptors. Oncol Res 2007;16:575-585.
187. Lu J, Pierron A, Ravid K. An adenosine analogue, IB-MECA, down-regulates estrogen receptor alpha and suppresses human breast cancer cell proliferation. Cancer Res 2003;63:705-713.
188. 3-mediated human glioblastoma cell proliferation. J Med Chem 2010;53:3954-3963.
189. Müller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Review article. Biochim Biophys Acta Biomembr (BBA) 2011;1808:1290-1308.
190. 3 adenosine receptor agonists. J Med Chem 2005;48:1745-1758.
191. Okamura T, Kurogi Y, Hashimoto K, Sato S, Nishikawa H, Kiryu K, Nagao Y. Structure-activity relationships of adenosine A3 receptor ligand: New potential therapy for the treatment of glaucoma. Bioorg Med Chem Lett 2004;14:3775-3779.
192. 3 adenosine receptors. Biochem Pharmacol 2003;65:1675-1684.
193. Ohno M, Gao ZG, Rompaey PV, Tchilibon S, Kim SK, Harris BA, Gross AS, Duong HT, Calenberghband SV, Jacobson KA. Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position. Bioorg Med Chem 2004;12:2995-3007.
194. 3-selective adenosine agonists. J Med Chem 1994;37:636-646.
195. 3 adenosine receptor. Mol Pharmacol 1994;45:1101-1111.
196. 3 adenosine receptors. J Med Chem 1994;37:3614-3621.
197. 3 adenosine receptors. J Med Chem 1996;39:802-806.
198. 3 adenosine receptor agonists. J Med Chem 1998;41:3174-3185.
199. 3 receptor. J Med Chem 2003;46:353-355.
200. 3 receptor ligands. Bioorg Med Chem 2006;14:1403-1412.
201. 2B ligands. J Med Chem 2002;45:3271-3279.
202. 3 adenosine receptor agonists. Bioorg Med Chem Lett 2006;16:2416-2418.
203. 3 adenosine receptor. J Med Chem 2007;50:1222-1230.
204. 3 adenosine receptor agonists, partial agonists, and antagonists. J Med Chem 2006;49:7373-7383.
205. 3 receptor agonists. J Med Chem 2004;47:4766-4773.
206. 3 receptor complementarity and activity for adenosine analogues modied in the ribose and purine moiety. Bioorg Med Chem 2005;13:973-983.
207. 3 receptor agonist. Tetrahed Lett 2009;50:2693-2696.
208. 3 adenosine receptor. Bioorg Med Chem 2006;14:4718-4730.
209. 3 adenosine receptors: Modication of the ribose moiety. Biochem Pharmacol 2004;67:893-901.
210. 3 adenosine receptor. J Med Chem 2006;49:273-281.
211. Mogensen JP, Roberts SM, Bowler AN, Thomsen C, Knutsen LJS. The synthesis of new adenosine A3 selective ligands containing bioisosteric isoxazoles. Bioorg Med Chem Lett 1998;8:1767-1770.
212. Lee K, Ravi G, Ji XD, Marquezb VE, Jacobson KA. Ring-constrained (N)-methanocarba nucleosides as adenosine receptor agonists: Independent 5'-uronamide and 2'-deoxy modications. Bioorg Med Chem Lett 2001;11:1333-1337.
213. 3 adenosine receptor-selective nucleosides containing a bicyclo [3.1.0] hexane ringsystem. J Med Chem 2009;52:7580-7592.
214. 3 adenosine receptor ligands: D-4'-thioadenosine derivatives without 4′-hydroxymethyl group as highly potent and selective antagonists. J Med Chem 2007;50:3159-3162.
215. 3 adenosine receptor antagonists. Bioorg Med Chem 2009;17:3733-3738.
216. 3 adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system. Bioorg Med Chem 2008;16:8546-8556.
217. Kim HO, Ji XD, Melman N, Olah ME, Stiles GL, Jacobson KA. Selective ligands for Rat A3-adenosine receptors: Structure-activity relationships of 1, 3-dialkylxanthine-7-riboside derivatives. J Med Chem 1994;37:4020-4030.
218. Chang LC, von Frijtag Drabbe Künzel JK, Mulder-Krieger T, Spanjersberg RF, Roerink SF, van den Hout G, Beukers MW, Brussee J, IJzerman AP. A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor. J Med Chem 2005;48:2405-2053.
219. 2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. J Med Chem 2004;47:3707-3709.
220. 3 adenosine receptor ligands: History and perspective. Med Res Rev 2000; 20:103-128.
221. Moro S, Gao ZG, Jacobson KA, Spalluto G. Progress in the pursuit of therapeutic adensine receptor antagonists. Med Res Rev 2006;26:131-159.
222. 3 adenosine receptor antagonists. Mini Rev Med Chem 2001;1:433-443.
223. 3 receptor ligands. Curr Top Med Chem 2003;3:445-462.
224. 2B-selective adenosine receptor antagonists. J Med Chem 2002;45:1500-1510.
225. 3 adenosine receptor. Proc Natl Acad Sci USA 1993;90:10365-10369.
226. 1 receptors. J Med Chem 1988;31:745-751.
227. 3 adenosine receptor antagonists. J Med Chem 2002;45:3337-3344.
228. 3 antagonist binding. ChemMedChem 2008;3:111-119.
229. 3 adenosine receptor antagonists. J Med Chem 2005;48:4697-4701.
230. 3 adenosine receptor antagonists. Bioorg Med Chem 2008;16:10281-10294.
231. 3-adenosine receptor antagonists. J Med Chem 2002;45:3440-3450.
232. 3 adenosine receptors. Bioorg Med Chem 2003;11:347-356.
233. 3 receptor antagonist. Eur J Pharmacol 2002;444:133-141.
234. Baraldi PG, Preti D, Zaid NA, Saponaro G, Tabrizi MA, Baraldi S, Romagnoli R, Moorman AR, Varani K, Cosconati S, Di Maro S, Marinelli L, Novellino E, Borea PA. New 2-heterocyclyl-imidazo[2, 1-i]purin-5-one derivatives as potent and selective human A(3) adenosine receptor antagonists. J Med Chem 2011;54:5205-5220.
235. 3 receptors. J Med Chem 1996;39:2980-2989.
236. 3 adenosine receptor antagonists. J Med Chem 1996;39:4667-4675.
237. 3 adenosine receptor antagonists. J Med Chem 1997;40:2596-2608.
238. 3 adenosine receptor antagonists. J Med Chem 1998;41:3186-3201.
239. 3 adenosine receptor antagonists. J Med Chem 1999;42:706-721.
240. 3 adenosine antagonists: Structural homology and receptor docking. J Chem Inf Comp Sci 1998;38:1239-1248.
241. 3 receptor antagonists. Bioorg Med Chem 2004;12:613-623.
242. 3 receptor antagonists. Curr Top Med Chem 2004;4:863-870.
243. 3 adenosine receptor antagonists. J Med Chem 2008;51:1764-1770.
244. Ji XD, Melman N, Jacobson KA. Interaction of flavonoids and other phytochemicals with adenosine receptors. J Med Chem 1996;39:781-788.
245. 3 adenosine receptor antagonists. J Med Chem 1996;39:2293-2301.
246. Moro S, van Rhee AM, Sanders LH, Jacobson KA. Flavonoid derivatives as adenosine receptor antagonists: A comparison of the hypothetical receptor binding site based on a comparative molecular field analysis model. J Med Chem 1998;4:46-52.
247. 3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives. J Med Chem 1998;41:3987-3993.
248. 3 receptor ligands. 2. Structure affinity profile of a series of isoquinoline and quinazoline compounds. J Med Chem 1998;41:3994-4000.
249. 3 receptor. J Med Chem 2000;43:2227-2238.
250. 3 adenosine receptor activation: Nucleoside ligands at the agonist/antagonist boundary. J Med Chem 2002;45:4471-4484.
251. 3 adenosine receptor agonists into selective antagonists by modification of the 5′-ribofuran-uronamide moiety. Bioorg Med Chem Lett 2006;16:596-601.
252. 3 adenosine receptor antagonists. J Med Chem 2008;51:6609-6613.
253. 3 adenosine receptor antagonists. Bioorg Med Chem Lett 2008;18:1612-1616.
254. 3 adenosine receptor. Bioorg Med Chem Lett 2001;11:1931-1934.
255. 3 receptor can explain their different biological behaviour. J Mol Graph Mod 2003;21:253-262.
256. Perreira M, Jiang J, Klutz AM, Gao ZG, Shainberg A, Lu C, Thomas CJ, Jacobson KA. Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem 2005;48:4910-4918.
257. Lenzi O, Colotta V, Catarzi D, Varano F, Poli D, Filacchioni G, Varani K, Vincenzi F, Borea PA, Paoletta S, Morizzo E, Moro S. 2-Phenylpyrazolo[4, 3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: New insights into the receptor-antagonist recognition. J Med Chem 2009;52:7640-7652.
258. 1 adenosine receptor antagonists. J Med Chem 2002;45:5030-5036.
259. 3 adenosine receptor antagonists: Synthesis, biochemical and molecular modeling studies. Bioorg Med Chem 2005;13:4679-4693.
260. Poli D, Catarzi D, Colotta V, Varano F, Filacchioni G, Daniele S, Trincavelli L, Martini C, Paoletta S, Moro S. The identification of the 2-phenylphthalazin-1(2H)-one scaffold as a new decorable core skeleton for the design of potent and selective human A3 adenosine receptor antagonists. J Med Chem 2011;54:2102-2113.
261. 3 adenosine receptor antagonist binding mode using a molecular simplification approach: From triazoloquinoxaline to a pyrimidine skeleton as a key study. J Med Chem 2007;50:6596-6606.
262. 3 adenosine receptors designed by 3D database searching. J Med Chem 2005;48:8253-8260.
263. 3 receptor subtype. J Med Chem 1996;39:4142-4148.
264. 3 receptor subtypes. J Med Chem 1998;41:2835-2845.
265. 3 receptor ligands. Bioorg Med Chem Lett 2004;14:2443-2446.
266. 2A adenosine antagonists. J Med Chem 1996;39:1164-1171.
267. 2A adenosine receptor antagonists. J Med Chem 1998;41:2126-2133.
268. 3 adenosine receptor antagonists. J Med Chem 1999;42:4473-4478.
269. 8 pyrazole nitrogen. J Med Chem 2000;43:4768-4780.
270. 3 adenosine receptor antagonists. J Med Chem 2002;45:770-780.
271. 3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations. J Med Chem 2006;49:1720-1729.
272. 3 adenosine receptor antagonists: Pyrazolo[4, 3-e]1, 2, 4-triazolo[1, 5-c]pyrimidine derivatives as a key study. J Med Chem 2005;48:152-162.
273. 3 adenosine receptor antagonist. J Med Chem 2002;45:3579-3582.
274. Cheong SL, Ann D, Kachler S, Paoletta S, Federico S, Cacciari B, Ant D, Klotz KN, Moro S, Spalluto G, Pastorin G. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA3 adenosine receptor's antagonists: New insights into structure-affinity-relationship and receptor-antagonist recognition. J Med Chem 2010;53:3361-3375.
275. 3 receptor ligands. J Med Chem 2002;45:3703-3708.
276. Colotta V, Catarzi D, Varano F, Cecchi L, Filacchioni G, Martini C, Trincavelli L, Lucacchini A. 1, 2, 4-triazolo[4, 3-a]quinoxalin-1-one: A versatile tool for the synthesis of potent and selective adenosine receptor antagonists. J Med Chem 2000;43:1158-1164.
277. Colotta V, Catarzi D, Varano F, Filacchioni G, Martini C, Trincavelli L, Lucacchini A. Synthesis and structure-activity relationships of a new set of 1, 2, 4-triazolo[4, 3-a]quinoxalin-1-one derivatives as adenosine receptor antagonists. Bioorg Med Chem 2003;11:3541-3550.
278. 3 adenosine receptor antagonists: Synthesis, pharmacological, and ligand-receptor modeling studies. J Med Chem 2004;47:3580-3590.
279. 3 receptor antagonist. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. J Med Chem 2006;49:3916-3925.
280. 3 adenosine receptor antagonists. Bioorg Med Chem 2008;16:6086-6102.
281. 3 adenosine receptor antagonists. Bioorg Med Chem 2005;13:705-715.
282. 3 adenosine receptor antagonists: Synthesis, biological evaluation and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives. J Med Chem 2005;48:7932-7945.
283. Colotta V, Catarzi D, Varano F, Cecchi L, Filacchioni G, Martini C, Trincavelli L, Lucacchini A. Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3, 4-c]quinoline derivatives as adenosine receptor antagonists. J Med Chem 2000;43;3118-3124.
284. 3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. J Med Chem 2007;50:4061-4074.
285. 3 adenosine receptor antagonists. J Med Chem 2005;48:5001-5008.
286. Colotta V, Lenzi O, Catarzi D, Varano F, Filacchioni G, Martini C, Trincavelli L, Ciampi O, Pugliese AM, Traini C, Pedata F, Morizzo E, Moro S. Pyrido[2, 3-e]-1, 2, 4-triazolo[4, 3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adensoine receptor antagonist. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. J Med Chem 2009;52:2407-2419.
287. 3 adenosine receptor antagonists. J Med Chem 2007;50:5676-5684.
288. 3 adenosine receptors. Biochem Pharmacol 2003;65:525-534.
289. 3 adenosine receptors. J Med Chem 2009;52:2098-2108.
290. 3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000. BMC Pharmacol 2008;8:20.
291. 3 adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol Pharmacol 2001;60:1057-1063.
292. 3 adenosine receptors by a series of imidazoquinoline derivatives. Mol Pharmacol 2002;6:81-89.
293. 3 adenosine receptor. J Med Chem 2006;49:3354-3361.
294. 3 receptor. J Med Chem 2009;52:926-931.
295. Gao ZG, Gross AS, Jacobson KA. Effects of the allosteric modulator SCH-202676 on adenosine and P2Y receptors. Life Sci 2004;74:3173-3180.
296. 3 adenosine receptor. Biochem Pharmacol 2010;79:48-56.
297. 3 receptor pharmacology by the food dye brilliant black BN: Evidence for allosteric interactions. Mol Pharmacol 2010;77:678-686.
298. 3 adenosine receptor. Mol Pharmacol 2003;63:1021-1031.
299. 3 adenosine receptor. Proc Natl Acad Sci 1993;90:10365-10369.
300. 3 adenosine receptors and stimulates mast cell degranulation. J Clin Invest 1997;100:2849-2857.
301. Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, Lohse MJ. Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn Schmiedberg's Arch Pharmacol 1998;357:1-9.
302. 3 adenosine receptor. Mol Pharmacol 1994;45:978982.
303. 3 adenosine receptor. Biochem Pharmacol 2010;79:967-973.
304. 3 adenosine receptor. Purin Signal 2009;5:31-37.
305. 3 receptor. Eur J Pharmacol 2007;556:14-18.
306. 3 adenosine receptors. Mol Pharmacol 2000;57:968-975.
307. 3 adenosine receptors in Jurkat T cells. Br J Pharmacol 2001;134:116-126.
308. 3 adenosine receptors in human neutrophils and promyelocytic HL60 cells. A pharmacological and biochemical study. Mol Pharmacol 2002;61:415-424.
309. 3 adenosine receptors. Bioorg Med Chem Lett 2002;12:501-503.
310. 3 adenosine receptor. J Biol Chem 2002;277;19056-19063.
311. 3 receptor. Nucl Med Biol 2008;35:61-66.
312. González MP, Terain C, Teijeira M. Search for new antagonist ligands for adenosine receptors from QSAR point of view. How close are we? Med Res Rev 2008;28:329-371.
313. Lewis RA. A general method for exploiting QSAR models in lead optimization. J Med Chem 2005;48:1638-1648.
314. Dudek AZ, Arod T, Galvez J. Computational methods in developing quantitative structure-activity relationships (QSAR): A review. Comb Chem High Throughput Screen 2006;9:213-228.
315. 3 adenosine receptor agonists. Bioorg Med Chem 1995;3:1331-1343.
316. Sharma BK, Pilania P, Singh P, Prabhakar YS. Combinatorial protocol in multiple linear regression/partial least-squares directed rationale for the caspase-3 inhibition activity of isoquinoline-1, 3, 4-trione derivatives. SAR QSAR Environ Res 2010;21:169-185.
317. 6-substituted-4′-thioadenosine-5′-uronamide. Eur J Med Chem 2009;44:1377-1382.
318. Roy K. QSAR of adenosine receptor antagonists. I: Exploration of receptor interaction sites of 1, 2-dihydro-2-phenyl-1, 2, 4-triazolo[4, 3-a]quinoxaline-1-one derivatives using AM1 calculations. Ind J Chem 2003;42B:1485-1496.
319. 3 receptor subtypes. QSAR Comb Sci 2003;22:614-621.
320. 3 receptor subtype. Bioorg Med Chem Lett 2004;14:3705-3709.
321. 3 receptor antagonists using FA and GFA techniques. Bioorg Med Chem 2005;13:1159-1165.
322. Borghini A, Pietra D, Domenichelli P, Bianucci AM. QSAR study on thiazole and thiadiazole analogues as antagonists for the adenosine A1 and A3 receptors. Bioorg Med Chem 2005;13:5330-5337.
323. 3 receptor antagonists. An approach to the optimization of protein models. J Med Chem 2006, 49, 4085-4097.
324. 3 adenosine receptor antagonists. Bioorg Med Chem Lett 2011;21:2898-2905.
325. 3 adenosine receptor antagonists. J Med Chem 2005;48:5698-5704.
326. Moro S, Bacilieri M, Ferrari C, Spalluto G. Autocorrelation of molecular electrostatic potential surface properties combined with partial least squares analysis as alternative attractive tool to generate ligand-based 3D-QSARs. Curr Drug Discov Technol 2005;2:13-21.
327. 3 receptor antagonists: An update. Curr Med Chem 2006;13:639-645.
328. 3 receptor pyrazolo-triazolo-pyrimidine antagonists binding sites. Bioorg Med Chem 2009;17:5259-5274.
329. Michielan L, Federico S, Terfloth L, Hristozov D, Cacciari B, Klotz KN, Spalluto G, Gasteiger J, Moro S. Exploring potency and selectivity receptor antagonist profiles using a multilabel classification approach: The human adenosine receptors as a key study. J Chem Inf Model 2009;49:2820-2836.
330. Moro S, Guo D, Camaioni E, Boyer JL, Harden TK, Jacobson KA. Human P2Y1 receptor: Molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J Med Chem 1998;41:1456-1466.
331. Moro S, Deflorian F, Spalluto G, Pastorin G, Cacciari B, Kim S-K, Jacobson KA. Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling. Chem Comm 2003;24:2949-2956.
332. Martinelli A, Tuccinardi T. Molecular modeling of adenosine receptors: New results and trends. Med Res Rev 2008;28:247-277.
333. 3 adenosine receptor as versatile G protein-coupled receptor example to validate the receptor homology modeling technology. Curr Pharm Des 2009;15:4069-4084.
334. Hibert MF, Trumpp-Kallmeyer S, Bruinvels A, Hoflack J. Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol Pharmacol 1991;40:8-15.
335. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000;289:739-745.
336. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007;318:1258-1265.
337. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SGF, Thian FS, Kobilka TS, Choi HJ, Yao XJ, Weis WI, Stevens RC, Kobilka BK. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 2007;318:1266-1273.
338. Rasmussen SGF, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VRP, Sanishvili R, Fischetti RF, Schertler GFX, Weis WI, Kobilka BK. Crystal structure of the human beta2 adrenergic G protein-coupled receptor. Nature 2007;450:383-387.
339. 2A adenosine receptor bound to an antagonist. Science 2008;322:1211-1217.
340. 2A adenosine receptor. Science 2011;332:322-327.
341. Evers A, Klebe G. Ligand-supported homology modeling of G protein-coupled receptor sites: Models sufficient for successful virtual screening. Angew Chem Int Ed 2004;43:248-251.
342. Evers A, Gohlke H, Klebe G. Ligand-supported homology modeling of protein binding-sites using knowledge-based potentials. J Mol Biol 2003;334:327-345.
343. Moro S, Deflorian F, Bacilieri M, Spalluto G. Ligand-based homology modeling as attractive tool to inspect GPCR structural plasticity. Curr Pharm Des 2006;12:2175-2185.
344. Katritch V, Kufareva I, Abagyan R. Structure based prediction of subtype-selectivity for adenosine receptor antagonists. Neuropharmacol 2011;60:108-115.
345. 3 receptor. Proteins 2011;79:1878-1897.
346. 2-adrenergic-based homology models through the docking studies. J Comp Chem 2008;30:14-32.
347. 3 adenosine receptor to probe interactions between the 2-position of adenosine analogs and Gln167 in the second extracellular loop. Nucleos Nucleot Nucl Acids 2005;24:1507-1517.
348. 3 receptor with selectively enhanced affinity for amine-modified nucleosides. J Med Chem 2001;44:4125-4136.
349. 3 adenosine receptors by site-directed mutagenesis. Biochem Biophys Res Commun 2001;284:596-601.
350. Ballesteros JA, Weinstein HW. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods Neurosci 1995;25:366-428.
351. 3 receptor agonists. Bioorg Med Chem 2010;18:7923-7930.
352. 3 adenosine receptor antagonists and pharmacophore-based drug design. Neurochem Int 2009;55:637-642.
353. Farrens DL, Altenbach C, Yang K, Hubbell WL, Khorana HG. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 1996;274:768-770.
354. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H, Kobilka BK. Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor. EMBO J 1997;16:6737-6747.
355. Jensen AD, Guarnieri F, Rasmussen SG, Asmar F, Ballesteros JA, Gether U. Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta 2 adrenergic receptor mapped by site-selective fluorescent labeling. J Biol Chem 2001;276:9279-9290.
356. Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SG, Shi L, Gether U, Javitch JA. Activation of the beta2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 2001;276:29171-29177.
357. Lin SW, Sakmar TP. Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry 1996;35:11149-11159.
358. Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, Javitch JA. Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem 2002;277:40989-40996.
359. 3 adenosine receptor. J Mol Grap Mod 2006;25:562-577.
360. 3 muscarinic acetylcholine receptor activation probed by the use of an in situ disulfide cross-linking strategy. J Biol Chem 2002;277:2247-2257.
361. 3 receptor: Agonist induced conformational changes of Trp243. J Comput Aided Mol Des 2006;20:673-684.
362. Crocker E, Eilers M, Ahuja S, Hornak V, Hirshfeld A, Sheves M, Smith SO. Location of Trp265 in metarhodopsin II: Implications for the activation mechanism of the visual receptor rhodopsin. J Mol Biol 2006;357:163-172.
363. 3 adenosine receptor (neoceptor) using tailored nucleoside agonists. J Med Chem 2006;49:2689-2702.
364. 2 adrenoceptor. Nature 2011;469:175-180.